Market revenue in 2023 | USD 10.4 million |
Market revenue in 2030 | USD 25.5 million |
Growth rate | 13.7% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 80.77% in 2023. Horizon Databook has segmented the UK mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of established research & development infrastructure and growing investment by the government are key drivers for market growth in this country. As part of UK Research and Innovation, in 2019, the Biotechnology and Biological Sciences Research Council (BBSRC) and Medical Research Council (MRC) provided around half of the national public sector investment in life sciences.
Advanced infrastructure and technology help researchers expedite research study, making it smarter and cheaper. For instance, researchers from the University of Manchester developed a miRBase searchable database of published miRNA sequences and annotations.
Companies from the UK are continuously innovating and expanding their product portfolios to support & aid life sciences research. For instance, Abcam Plc has an extensive product portfolio of approximately 110,000, which includes antibodies, proteins, lysates, biochemicals, kits, and assays for various scientific research.
Horizon Databook provides a detailed overview of country-level data and insights on the UK mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into UK mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account